Gameto lands $44m to advance fertility and menopause programs

Biotech gears up for potential Fertilo approval while accelerating development of menopause-targeting therapies. Women’s health biotech Gameto has secured $44 million in Series C financing to advance its work in stem cell–derived therapies for reproductive health. The company says the funding will allow it to complete its Phase 3 trial of its infertility program Fertilo […] The post Gameto lands $44m to advance fertility and menopause programs appeared first on Longevity.Technology.